false Q3 --06-30 0001865468 00-0000000 0001865468 2024-07-01 2025-03-31 0001865468 KACL:UnitsEachConsistingOfOneOrdinaryShare0.0001ParValueOnehalf12OfOneRedeemableWarrantAndOneRightEntitlingHolderToReceiveOnetenthOfOrdinaryShareMember 2024-07-01 2025-03-31 0001865468 KACL:OrdinarySharesParValue0.0001PerShareMember 2024-07-01 2025-03-31 0001865468 KACL:RedeemableWarrantsEachExercisableForOneOrdinaryShareAtExercisePriceOf11.50IncludedAsPartOfUnitsMember 2024-07-01 2025-03-31 0001865468 KACL:RightsEachToReceiveOnetenthOfOneOrdinaryShareMember 2024-07-01 2025-03-31 0001865468 2025-07-15 0001865468 2025-03-31 0001865468 2024-06-30 0001865468 2025-01-01 2025-03-31 0001865468 2024-01-01 2024-03-31 0001865468 2023-07-01 2024-03-31 0001865468 KACL:RedeemableOrdinarySharesMember 2025-01-01 2025-03-31 0001865468 KACL:RedeemableOrdinarySharesMember 2024-01-01 2024-03-31 0001865468 KACL:RedeemableOrdinarySharesMember 2024-07-01 2025-03-31 0001865468 KACL:RedeemableOrdinarySharesMember 2023-07-01 2024-03-31 0001865468 KACL:NonRedeemableOrdinarySharesMember 2025-01-01 2025-03-31 0001865468 KACL:NonRedeemableOrdinarySharesMember 2024-01-01 2024-03-31 0001865468 KACL:NonRedeemableOrdinarySharesMember 2024-07-01 2025-03-31 0001865468 KACL:NonRedeemableOrdinarySharesMember 2023-07-01 2024-03-31 0001865468 us-gaap:CommonStockMember 2023-06-30 0001865468 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001865468 us-gaap:RetainedEarningsMember 2023-06-30 0001865468 2023-06-30 0001865468 us-gaap:CommonStockMember 2023-09-30 0001865468 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001865468 us-gaap:RetainedEarningsMember 2023-09-30 0001865468 2023-09-30 0001865468 us-gaap:CommonStockMember 2023-12-31 0001865468 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001865468 us-gaap:RetainedEarningsMember 2023-12-31 0001865468 2023-12-31 0001865468 us-gaap:CommonStockMember 2024-06-30 0001865468 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001865468 us-gaap:RetainedEarningsMember 2024-06-30 0001865468 us-gaap:CommonStockMember 2024-09-30 0001865468 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001865468 us-gaap:RetainedEarningsMember 2024-09-30 0001865468 2024-09-30 0001865468 us-gaap:CommonStockMember 2024-12-31 0001865468 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001865468 us-gaap:RetainedEarningsMember 2024-12-31 0001865468 2024-12-31 0001865468 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001865468 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001865468 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001865468 2023-07-01 2023-09-30 0001865468 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001865468 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0001865468 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0001865468 2023-10-01 2023-12-31 0001865468 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001865468 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001865468 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001865468 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001865468 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001865468 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001865468 2024-07-01 2024-09-30 0001865468 us-gaap:CommonStockMember 2024-10-01 2024-12-31 0001865468 us-gaap:AdditionalPaidInCapitalMember 2024-10-01 2024-12-31 0001865468 us-gaap:RetainedEarningsMember 2024-10-01 2024-12-31 0001865468 2024-10-01 2024-12-31 0001865468 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001865468 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001865468 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001865468 us-gaap:CommonStockMember 2024-03-31 0001865468 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001865468 us-gaap:RetainedEarningsMember 2024-03-31 0001865468 2024-03-31 0001865468 us-gaap:CommonStockMember 2025-03-31 0001865468 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001865468 us-gaap:RetainedEarningsMember 2025-03-31 0001865468 us-gaap:IPOMember 2021-12-16 2021-12-16 0001865468 us-gaap:OverAllotmentOptionMember KACL:UnderwriterMember 2021-12-16 0001865468 us-gaap:OverAllotmentOptionMember KACL:UnderwriterMember 2021-12-16 2021-12-16 0001865468 us-gaap:PrivatePlacementMember KACL:KairousAsiaLimitedMember 2021-12-16 2021-12-16 0001865468 us-gaap:PrivatePlacementMember KACL:KairousAsiaLimitedMember 2021-12-16 0001865468 KACL:OptionsMember KACL:UnderwriterMember 2021-12-16 2021-12-16 0001865468 2021-12-16 2021-12-16 0001865468 us-gaap:CashMember 2021-12-16 0001865468 2021-12-16 0001865468 KACL:InitialPublicOfferingAndPrivatePlacementMember 2021-12-16 2021-12-16 0001865468 KACL:InitialPublicOfferingAndPrivatePlacementMember 2021-12-16 0001865468 us-gaap:IPOMember srt:ManagementMember 2025-03-31 0001865468 KACL:PublicWarrantMember 2025-03-31 0001865468 us-gaap:UnsecuredDebtMember 2022-12-14 2022-12-14 0001865468 us-gaap:UnsecuredDebtMember 2023-03-10 2023-03-10 0001865468 KACL:PromissoryNoteMember KACL:SponsorMember 2023-11-10 0001865468 2023-12-14 0001865468 KACL:SponsorMember KACL:PromissoryNoteMember 2024-10-16 0001865468 2024-12-06 0001865468 KACL:SponsorMember KACL:PromissoryNoteMember 2025-04-16 0001865468 us-gaap:SubsequentEventMember 2025-05-16 0001865468 KACL:AffiliateSponsorMember 2023-05-10 0001865468 us-gaap:IPOMember 2025-03-31 0001865468 KACL:AmendedAndRestatedMergerAgreementMember 2024-07-18 2024-07-18 0001865468 KACL:AmendedAndRestatedMergerAgreementMember KACL:PurchaserOrdinarySharesMember 2024-07-18 2024-07-18 0001865468 us-gaap:IPOMember 2024-07-01 2025-03-31 0001865468 KACL:DeferredUnderwritingCommissionsMember 2024-07-01 2025-03-31 0001865468 us-gaap:CommonStockMember 2022-07-01 2023-06-30 0001865468 us-gaap:CommonStockMember 2023-12-14 2024-12-14 0001865468 us-gaap:CommonStockMember 2023-12-14 2023-12-14 0001865468 us-gaap:CommonStockMember 2024-12-12 2024-12-12 0001865468 2022-07-01 2023-06-30 0001865468 2023-07-01 2024-06-30 0001865468 us-gaap:IPOMember 2021-12-16 0001865468 KACL:PublicWarrantMember 2021-12-16 0001865468 us-gaap:OverAllotmentOptionMember KACL:UnderwriterMember KACL:PublicWarrantMember 2021-12-16 2021-12-16 0001865468 us-gaap:PrivatePlacementMember 2021-12-16 2021-12-16 0001865468 us-gaap:PrivatePlacementMember 2021-12-16 0001865468 KACL:FounderSharesMember 2021-05-13 2021-05-13 0001865468 KACL:FounderSharesMember 2021-10-21 2021-10-21 0001865468 KACL:FounderSharesMember 2021-05-13 0001865468 KACL:FounderSharesMember 2021-10-21 0001865468 KACL:FounderSharesMember us-gaap:OverAllotmentOptionMember 2021-05-13 2021-05-13 0001865468 KACL:FounderSharesMember us-gaap:OverAllotmentOptionMember 2021-10-21 2021-10-21 0001865468 KACL:SponsorMember us-gaap:OverAllotmentOptionMember 2025-03-31 0001865468 KACL:BusinessAcquisitionMember 2024-07-01 2025-03-31 0001865468 KACL:SponsorMember 2024-07-01 2025-03-31 0001865468 KACL:SponsorMember 2025-01-01 2025-03-31 0001865468 KACL:SponsorMember 2024-01-01 2024-03-31 0001865468 KACL:SponsorMember 2023-07-01 2024-03-31 0001865468 KACL:NRInstantProducePCLMember 2024-01-01 2024-01-01 0001865468 KACL:NRInstantProducePCLMember 2025-01-01 2025-03-31 0001865468 KACL:NRInstantProducePCLMember 2024-01-01 2024-03-31 0001865468 KACL:NRInstantProducePCLMember 2024-07-01 2025-03-31 0001865468 KACL:NRInstantProducePCLMember 2023-07-01 2024-03-31 0001865468 KACL:NRInstantProducePCLMember 2024-01-01 2025-03-31 0001865468 KACL:NRInstantProducePCLMember 2025-03-31 0001865468 KACL:NRInstantProducePCLMember 2024-06-30 0001865468 KACL:WorkingCapitalNoteMember KACL:SponsorMember 2021-04-23 0001865468 KACL:WorkingCapitalNoteMember KACL:SponsorMember 2021-05-12 0001865468 KACL:WorkingCapitalNoteMember KACL:SponsorMember 2024-02-13 0001865468 KACL:WorkingCapitalNoteMember KACL:SponsorMember 2023-09-18 0001865468 KACL:WorkingCapitalNoteMember KACL:SponsorMember 2023-10-25 0001865468 KACL:WorkingCapitalNoteMember KACL:SponsorMember 2024-02-27 0001865468 KACL:WorkingCapitalNoteMember 2025-03-31 0001865468 KACL:WorkingCapitalNoteMember 2024-06-30 0001865468 KACL:PromissoryNoteMember KACL:SponsorMember 2022-12-14 0001865468 KACL:PromissoryNoteMember KACL:SponsorMember 2023-03-10 0001865468 KACL:InvestmentManagementTrustAgreementMember 2024-12-16 0001865468 KACL:SponsorMember KACL:PromissoryNoteMember 2024-11-16 0001865468 KACL:InvestmentManagementTrustAgreementMember srt:ScenarioForecastMember 2026-06-16 0001865468 KACL:SponsorMember KACL:PromissoryNoteMember 2025-05-17 0001865468 KACL:UnderwriterMember 2021-12-16 2021-12-16 0001865468 KACL:UnderwriterMember 2021-12-16 0001865468 us-gaap:OverAllotmentOptionMember 2021-12-16 2021-12-16 0001865468 us-gaap:IPOMember 2022-12-08 2022-12-08 0001865468 2022-12-08 0001865468 2022-12-08 2022-12-08 0001865468 2023-06-14 2023-06-14 0001865468 KACL:AmendedAndRestatedMergerAgreementMember 2023-09-30 2023-09-30 0001865468 KACL:AmendedAndRestatedMergerAgreementMember KACL:PurchaserOrdinarySharesOneMember 2024-09-25 2024-09-25 0001865468 KACL:AmendedAndRestatedMergerAgreementMember KACL:PurchaserOrdinarySharesOneMember KACL:ConditionOneMember 2024-09-25 0001865468 KACL:AmendedAndRestatedMergerAgreementMember KACL:PurchaserOrdinarySharesOneMember KACL:ConditionOneMember 2024-09-25 2024-09-25 0001865468 KACL:AmendedAndRestatedMergerAgreementMember KACL:PurchaserOrdinarySharesOneMember KACL:ConditionTwoMember 2024-09-25 0001865468 KACL:AmendedAndRestatedMergerAgreementMember KACL:PurchaserOrdinarySharesOneMember KACL:ConditionTwoMember 2024-09-25 2024-09-25 0001865468 KACL:AmendedAndRestatedMergerAgreementMember KACL:PurchaserOrdinarySharesOneMember KACL:ConditionThreeMember 2024-09-25 0001865468 KACL:AmendedAndRestatedMergerAgreementMember KACL:PurchaserOrdinarySharesOneMember KACL:ConditionThreeMember 2024-09-25 2024-09-25 0001865468 KACL:AmendedAndRestatedMergerAgreementMember KACL:PurchaserOrdinarySharesTwoMember 2024-09-25 2024-09-25 0001865468 KACL:AmendedAndRestatedMergerAgreementMember KACL:ConditionOneMember 2024-09-25 2024-09-25 0001865468 KACL:AmendedAndRestatedMergerAgreementMember KACL:PurchaserOrdinarySharesTwoMember KACL:ConditionOneMember 2024-09-25 2024-09-25 0001865468 KACL:AmendedAndRestatedMergerAgreementMember KACL:ConditionTwoMember 2024-09-25 2024-09-25 0001865468 KACL:AmendedAndRestatedMergerAgreementMember KACL:PurchaserOrdinarySharesTwoMember KACL:ConditionTwoMember 2024-09-25 2024-09-25 0001865468 KACL:SharePurchaseAgreementMember KACL:SponsorMember KACL:KairousAsiaLimitedMember 2023-06-30 2023-06-30 0001865468 KACL:SharePurchaseAgreementMember KACL:SponsorMember KACL:KairousAsiaLimitedMember 2023-06-30 0001865468 KACL:SponsorMember KACL:KairousAsiaLimitedMember 2023-06-30 0001865468 KACL:SponsorMember KACL:KairousAsiaLimitedMember 2023-06-30 2023-06-30 0001865468 KACL:FacilityAgreementMember 2023-09-15 0001865468 KACL:ShareMortgageMember 2023-09-15 0001865468 KACL:FacilityAgreementMember 2024-09-25 2024-09-25 0001865468 KACL:FacilityAgreementMember 2024-11-01 2024-11-01 0001865468 KACL:RegenerationCapitalLimitedMember KACL:SharePurchaseAgreementMember 2024-08-23 2024-08-23 0001865468 KACL:RegenerationCapitalLimitedMember KACL:SharePurchaseAgreementMember 2024-08-23 0001865468 KACL:RegenerationCapitalLimitedMember KACL:SharePurchaseAgreementMember KACL:KairousAsiaLimitedMember 2024-08-23 0001865468 KACL:SharePurchaseAgreementMember KACL:RegenerationCapitalLimitedMember KACL:MsBenyapaRungruangnavaratMember 2024-09-17 2024-09-17 0001865468 KACL:SharePurchaseAgreementMember KACL:RegenerationCapitalLimitedMember KACL:MsBenyapaRungruangnavaratMember 2024-09-17 0001865468 KACL:SharePurchaseAgreementMember KACL:RegenerationCapitalLimitedMember KACL:KairousAsiaLimitedMember KACL:MsBenyapaRungruangnavaratMember 2024-09-17 0001865468 KACL:ShareRepurchaseAgreementMember KACL:RegenerationCapitalLimitedMember KACL:MsBenyapaRungruangnavaratMember us-gaap:SubsequentEventMember 2025-06-24 2025-06-24 0001865468 us-gaap:WarrantMember 2025-03-31 0001865468 us-gaap:WarrantMember 2024-07-01 2025-03-31 0001865468 KACL:TwoUnsecuredPromissoryNotesMember KACL:SponsorMember 2025-03-14 0001865468 us-gaap:SubsequentEventMember KACL:TwoUnsecuredPromissoryNotesMember KACL:SponsorMember 2025-04-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares KACL:Vote xbrli:pure iso4217:THB

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(MARK ONE)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarter ended March 31, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-41155

Kairous Acquisition Corp. Limited

(Exact Name of Registrant as Specified in Its Charter)

Cayman Islands

n/a

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

Level 39 Marina Bay Financial Centre Tower 2,

10 Marina Boulevard,

City Singapore 018983, Singapore

(Address of principal executive offices)

Tel: +662-255-6851340

(Issuer’s telephone number)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging Growth Company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Units, each consisting of one ordinary share, $0.0001 par value, one-half (1/2) of one redeemable warrant and one right entitling the holder to receive one-tenth of an ordinary share	KACUF	OTC Markets Group, Inc.
Ordinary shares, par value $0.0001 per share	KACLF	OTC Markets Group, Inc.
Redeemable warrants, each exercisable for one ordinary share at an exercise price of $11.50 included as part of the units	KACWF	OTC Markets Group, Inc.
Rights, each to receive one-tenth of one ordinary share	KACRF	OTC Markets Group, Inc.

As of July 15,2025, 3,164,938 ordinary shares, par value $0.0001 per share, were issued and outstanding.

Kairous Acquisition Corp. Limited

FORM 10-Q FOR QUARTER ENDED MARCH 31, 2025

TABLE OF CONTENTS

		Page
PART 1 – FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Financial Statements	F-1
	Unaudited Condensed Consolidated Balance Sheets as of March 31, 2025 and June 30, 2024	F-1
	Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended March 31, 2025 and 2024	F-2
	Unaudited Condensed Consolidated Statements of Changes in Shareholders’ Deficit for the Three and Nine Months Ended March 31, 2025 and 2024	F-3
	Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended March 31, 2025 and 2024	F-4
	Notes to Unaudited Condensed Consolidated Financial Statements	F-5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	8
Item 4.	Controls and Procedures	8
PART II – OTHER INFORMATION		9
Item 1.	Legal Proceedings	9
Item 1A.	Risk Factors	9
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	9
Item 3.	Defaults Upon Senior Securities	9
Item 4.	Mine Safety Disclosures	9
Item 5.	Other Information	9
Item 6.	Exhibits	9
SIGNATURES		10

PART I – FINANCIAL STATEMENTS

KAIROUS ACQUISITION CORP. LIMITED

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31, 2025			June 30, 2024
	(unaudited)
ASSETS
Current Assets:
Cash	$	—		$	985
Prepaid expenses and other current assets		2,356			72,202
Total Current Assets		2,356			73,187

Cash held in the Trust Account		10,599,917			16,152,108
Total Assets	$	10,602,273		$	16,225,295

LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS’ DEFICIT
Current liabilities:
Accounts payable and accrued expenses	$	745,752		$	307,654
Extension loans – sponsor		2,240,000			1,790,000
Working capital note - sponsor		1,375,341			1,111,370
Total Current Liabilities		4,361,093			3,209,024

Deferred underwriting commission		2,730,000			2,730,000
Total Liabilities		7,091,093			5,939,024

COMMITMENTS AND CONTINGENCIES (Note 6)		-			-

Ordinary shares subject to possible redemption, $0.0001 par value; 818,795 shares and 1,337,763 shares outstanding at March 31, 2025 and June 30, 2024, respectively (at redemption value)		10,599,917			16,152,108

Shareholders’ Deficit:
Ordinary shares, $0.0001 par value, 500,000,000 shares authorized, 2,346,143 shares issued and outstanding at March 31, 2025 and June 30, 2024 (excluding 818,795 and 1,337,763 shares subject to possible redemption at March 31, 2025 and June 30, 2024, respectively)		235			235
Accumulated deficit		(7,088,972	)		(5,866,072	)
Total Shareholders’ Deficit		(7,088,737	)		(5,865,837	)
Total Liabilities, Ordinary Shares Subject to Possible Redemption and Shareholders’ Deficit	$	10,602,273		$	16,225,295

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

F-1

KAIROUS ACQUISITION CORP. LIMITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	2025			2024			2025			2024
	For the Three Months Ended March 31,						For the Nine Months Ended March 31,
	2025			2024			2025			2024
Revenues	$	-		$	-		$	-		$	-

Expenses
Administration fee - related party		15,000			15,000			45,000			45,000
General and administrative		154,870			143,295			727,900			697,178
Total expenses		169,870			158,295			772,900			742,178

Loss from operations		(169,870	)		(158,295	)		(772,900	)		(742,178	)

Other income:
Interest income		-			-			-			1
Income earned on cash held in Trust Account		109,764			204,839			500,445			812,040
Total other income		109,764			204,839			500,445			812,041

Net (loss) income attributable to ordinary shares	$	(60,106	)	$	46,544		$	(272,455	)	$	69,863

Weighted average shares outstanding, redeemable ordinary shares – Basic and diluted		818,795			1,337,763			1,131,312			1,794,464
Net (loss) income per ordinary share, redeemable ordinary shares – Basic and diluted	$	(0.02	)	$	0.01		$	(0.08	)	$	0.02

Weighted average shares outstanding, non-redeemable ordinary shares – Basic and diluted		2,346,143			2,346,143			2,346,143			2,346,143
Net (loss) income per ordinary share, non-redeemable ordinary shares – Basic and diluted	$	(0.02	)	$	0.01		$	(0.08	)	$	0.02

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

F-2

KAIROUS ACQUISITION CORP. LIMITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDER’S DEFICIT

For the Three and Nine Months Ended March 31, 2024

	Shares		Amount		Capital		Deficit			Deficit
	Ordinary Shares				Additional Paid-in		Accumulated			Total Shareholders’
	Shares		Amount		Capital		Deficit			Deficit
Balance, June 30, 2023		2,346,143	$	235	$	—	$	(4,001,704	)	$	(4,001,469	)
Current period remeasurement adjustment of ordinary shares to redemption value		—		—		—		(659,668	)		(659,668	)
Net loss		—		—		—		(57,815	)		(57,815	)
Balance, September 30, 2023		2,346,143	$	235	$	—	$	(4,719,187	)	$	(4,718,952	)
Current period remeasurement adjustment of ordinary shares to redemption value		—		—		—		(597,533	)		(597,533	)
Net income		—		—		—		81,134			81,134
Balance, December 31, 2023		2,346,143	$	235	$	—	$	(5,235,586	)	$	(5,235,351	)
Current period remeasurement adjustment of ordinary shares to redemption value		—		—		—		(354,839	)		(354,839	)
Net income		—		—		—		46,544			46,544
Balance, March 31, 2024		2,346,143	$	235	$	—	$	(5,543,881	)	$	(5,543,646	)

For the Three and Nine Months Ended March 31, 2025

Balance, June 30, 2024	2,346,143	$	235	$	—	$	(5,866,072	)	$	(5,865,837	)

Current period remeasurement adjustment of ordinary shares to redemption value	—		—		—		(363,883	)		(363,883	)
Net loss	—		—		—		(16,891	)		(16,891	)
Balance, September 30, 2024	2,346,143	$	235	$	—	$	(6,246,846	)	$	(6,246,611	)
Current period remeasurement adjustment of ordinary shares to redemption value	—		—		—		(326,798	)		(326,798	)
Net loss	—		—		—		(195,458	)		(195,458	)
Balance, December 31, 2024	2,346,143	$	235	$	—	$	(6,769,102	)	$	(6,768,867	)
Balance	2,346,143	$	235	$	—	$	(6,769,102	)	$	(6,768,867	)
Current period remeasurement adjustment of ordinary shares to redemption value	—		—		—		(259,764	)		(259,764	)
Net loss	—		—		—		(60,106	)		(60,106	)
Net (loss) income	—		—		—		(60,106	)		(60,106	)
Balance, March 31, 2025	2,346,143	$	235	$	—	$	(7,088,972	)	$	(7,088,737	)
Balance	2,346,143	$	235	$	—	$	(7,088,972	)	$	(7,088,737	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

F-3

KAIROUS ACQUISITION CORP. LIMITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	2025			2024
	For the Nine Months Ended March 31,
	2025			2024
Cash Flows from Operating Activities:
Net (loss) income	$	(272,455	)	$	69,863
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Income earned on cash and investments held in Trust Account		(500,445	)		(812,040	)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		69,846			56,086
Accounts payable and accrued expenses		438,098			186,051
Net cash used in operating activities		(264,956	)		(500,040	)

Cash Flows from Investing Activities:
Cash deposited into Trust Account		(450,000	)		(800,000	)
Cash withdrawn from Trust Account in connection with redemption		6,502,636			8,621,702
Net cash provided by investing activities		6,052,636			7,821,702

Cash Flows from Financing Activities:
Redemption of ordinary shares		(6,502,636	)		(8,621,702	)
Proceeds from sponsor for extension loans		450,000			800,000
Proceeds from sponsor for working capital note		263,971			461,066
Net cash used in financing activities		(5,788,665	)		(7,360,636	)

Net change in cash		(985	)		(38,974	)
Cash at beginning of period		985			39,359
Cash at end of period	$	—		$	385

Supplemental disclosure of non-cash financing activities:
Current period remeasurement adjustment of ordinary shares to redemption value	$	950,445		$	1,612,040

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

F-4

KAIROUS ACQUISITION CORP. LIMITED

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2025 AND 2024

NOTE 1 — DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS

Kairous Acquisition Corp. Limited (the “Company”) was incorporated in the Cayman Islands on March 24, 2021. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company is not limited to a particular industry or sector for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies.

On October 5, 2022, the Company set up KAC Merger Sub 1, a Cayman Islands exempted company and wholly owned subsidiary of the Company. On October 5, 2022, KAC Merger Sub 1 set up KAC Merger Sub 2, a Cayman Islands exempted company and wholly owned subsidiary of KAC Merger Sub 1.

As of March 31, 2025, the Company had not commenced any operations. All activity for the period from March 24, 2021 (inception) through March 31, 2025 relates to the Company’s formation and the initial public offering (“Initial Public Offering”), which is described below, and negotiation and consummation of an initial Business Combination. The Company will not generate any operating revenues until after the completion an initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering. The Company has selected June 30 as its fiscal year end.

As discussed below and in Note 8, the Company is in the process of liquidating the Trust Account and redeeming the Public Shares. See Note 8 for additional information about this process, including the Board of Directors’ intention to remove the obligation to liquidate and dissolve the Company.

The registration statement for the Company’s Initial Public Offering was declared effective on December 13, 2021. On December 16, 2021, the Company consummated the Initial Public Offering of 7,500,000 units (“Units” and, with respect to the ordinary shares included in the Units being offered, the “Public Shares”), generating gross proceeds of $75,000,000, which is described in Note 3. The Company granted the underwriter a 45-day option from the date of Initial Public Offering to purchase up to 1,125,000 additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts and commissions. On December 16, 2021, the underwriters partially exercised the over-allotment option by purchasing 300,000 additional units, generating $3,000,000. The underwriter has further indicated that they will not exercise the remaining over-allotment option, hence the remaining 825,000 units were forfeited.

Simultaneously with the closing of the Initial Public Offering, the Company consummated the private sale (the “Private Placement”) of an aggregate of 348,143 Units (the “Private Placement Units”) to Kairous Asia Limited (the “Sponsor”) at a purchase price of $10.00 per Private Placement Units, generating gross proceeds to the Company in the amount of $3,481,430. On December 16, 2021, the underwriters partially exercised the option at which time the Sponsor purchased 9,000 additional units, generating $90,000.

As of December 16, 2021, transaction costs amounted to $4,843,252 consisting of $1,559,900 of underwriting fees, $2,730,000 of deferred underwriting fees payable (which are held in a trust account with Continental Stock Transfer & Trust Company acting as trustee (the “Trust Account”) and $553,352 of other offering costs related to the Initial Public Offering. Cash of $857,408 was held outside of the Trust Account on December 16, 2021 and was available for working capital purposes. As described in Note 6, the $2,730,000 deferred underwriting fees are contingent upon the consummation of the Business Combination within 36 months from the closing of the Initial Public Offering. The Company is in the process of liquidating the Trust Account and redeeming the Public Shares. The deferred underwriting fee will be not reversed until the Trust Account is liquidated.

Following the closing of the Initial Public Offering on December 16, 2021, an amount of $78,780,000 ($10.10 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the Private Placement was placed in the Trust Account which may be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 185 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the consummation of a Business Combination or (ii) the distribution of the Trust Account, as described below.

F-5

The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The stock exchange listing rules require that the Business Combination must be with one or more operating businesses or assets with a fair market value equal to at least 80% of the assets held in the Trust Account (as defined below) (excluding the amount of deferred underwriting commissions and taxes payable on the income earned on the Trust Account). The Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). There is no assurance that the Company will be able to successfully effect a Business Combination. Upon the closing of the Initial Public Offering, management has agreed that $10.00 per Unit sold in the Initial Public Offering, including proceeds of the sale of the Private Placement Units, will be held in a trust account (the “Trust Account”) and invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund investing solely in U.S. Treasuries and meeting certain conditions under Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of (i) the completion of a Business Combination and (ii) the distribution of the funds in the Trust Account to the Company’s shareholders, as described below.

The Company will provide the holders of the outstanding Public Shares (the “Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer in connection with the Business Combination. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.10 per Public Share, plus any pro rata interest then in the Trust Account, net of taxes payable). The Public Shares subject to redemption will be recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering in accordance with the Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.”

All of the Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, if there is a shareholder vote or tender offer in connection with the Company’s Business Combination and in connection with certain amendments to the Company’s amended and restated certificate of incorporation (the “Certificate of Incorporation”). In accordance with the rules of the U.S. Securities and Exchange Commission (the “SEC”) and its guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of a company require ordinary shares subject to possible redemption to be classified outside of permanent equity. Given that the Public Shares will be issued with other freestanding instruments (i.e., public warrants), the initial carrying value of the ordinary shares classified as temporary equity will be the allocated proceeds determined in accordance with ASC 470-20. The ordinary shares are subject to ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, the Company has the option to either (i) accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or (ii) recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company has elected to recognize the changes immediately. The Public Shares are redeemable and will be classified as such on the balance sheet until such date that a redemption event takes place. Redemptions of the Company’s Public Shares may be subject to the satisfaction of conditions, including minimum cash conditions, pursuant to an agreement relating to the Company’s Business Combination.

F-6

If the Company seeks shareholder approval of the Business Combination, the Company will proceed with a Business Combination only if the Company receives an ordinary resolution under Cayman Islands law approving a Business Combination, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the Company, or such other vote as required by law or stock exchange rule. If a shareholder vote is not required and the Company does not decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (the “SEC”), and file tender offer documents containing substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination. If the Company seeks shareholder approval in connection with a Business Combination, the Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the Initial Public Offering in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares, without voting, and if they do vote, irrespective of whether they vote for or against a proposed Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective of whether they vote for or against the proposed transaction.

Notwithstanding the foregoing, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the Public Shares without the Company’s prior written consent.

The Sponsor has agreed (a) to waive its redemption rights with respect to any Founder Shares and Public Shares held by it in connection with the completion of a Business Combination and (b) not to propose an amendment to the Amended and Restated Memorandum and Articles of Association (i) to modify the substance or timing of the Company’s obligation to allow redemption in connection with the Company’s initial Business Combination or to redeem 100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii) with respect to any other provision relating to shareholders’ rights or pre-initial business combination activity, unless the Company provides the Public Shareholders with the opportunity to redeem their Public Shares upon approval of any such amendment.

If the Company has not completed a Business Combination within 12 months (or up to 36 months, if we extend the time to complete a business combination) from the closing of the Initial Public Offering (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem 100% of the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned and not previously released to us to pay our taxes, if any (less up to $50,000 of interest to pay dissolution expenses), divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the rights of the Public Shareholders as shareholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining Public Shareholders and its Board of Directors, liquidate and dissolve, subject in each case to the Company’s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.

On December 14, 2022 and March 10, 2023, the Company issued two unsecured promissory notes, each in an amount of $360,000, to the Sponsor in exchange for Sponsor depositing such amount into the Company’s trust account in order to extend the amount of time it has available to complete a business combination until June 16, 2023. From June 9, 2023 through November 10, 2023, the Company entered into six unsecured promissory note arrangements with the Sponsor, each in an amount of $120,000, in exchange for Sponsor depositing such amount into the Company’s trust account in order to extend the amount of time it has available to complete a business combination until December 16, 2023. The Sponsor deposited such amount into the Company’s trust account.

F-7

On December 14, 2023, the shareholders approved the amendment to the investment management trust agreement, pursuant to which the Company has the right to extend the time to complete a business combination twelve (12) times for an additional one (1) month each time from December 16, 2023 to December 16, 2024 by depositing into the trust account $50,000 for each one-month extension. On December 15, 2023 through November 16, 2024, the Company issued 12 unsecured promissory notes, each in an amount of $50,000, to the Sponsor in exchange for Sponsor depositing such amount into the Company’s trust account in order to extend the amount of time it has available to complete a business combination until December 16, 2024.

On December 6, 2024, the shareholders approved the second amendment to the investment management trust agreement, pursuant to which the Company has the right to extend the time to complete a business combination six (6) times for an additional one (1) month each time from December 16, 2024 to June 16, 2025 by depositing into the trust account $50,000 for each one-month extension. On December 16, 2024 through April 16, 2025, the Company issued 5 unsecured promissory notes, each in an amount of $50,000, to the Sponsor in exchange for Sponsor depositing such amount into the Company’s trust account in order to extend the amount of time it has available to complete a business combination until May 16, 2025. On May 16, 2025, the Company failed to properly extend the business combination period to June 16, 2025, as it did not deposit $50,000 to the trust account in order to extend the date by which it must consummate an initial business combination (the “Termination Date”) to beyond May 16, 2025. Under the Company’s Fourth Amended and Restated Memorandum and Articles of Association (the “Charter”), if the Company does not consummate an initial business combination by the Termination Date, the Company is required to (i) immediately commence a wind down of operations, (ii) as promptly as reasonably possible but not more than ten business days thereafter, liquidate the Trust Account and redeem all of the outstanding public ordinary shares (“Public Shares”) that were included in the units issued in its initial public offering, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining members and the directors, liquidate and dissolve.

The Company is in process of liquidating the trust account and redeeming the Public Shares. The proceeds of the trust account are now held in a trust operating account at Citibank, N.A, for the purpose of disbursement to the holders of the Public Shares. Record holders will receive their pro rata portion of the proceeds of the trust account by delivering their Public Shares to Continental Stock Transfer & Trust Company, the Company’s transfer agent.

The board of directors of the Company intends to seek to amend the Charter to remove the obligation to liquidate and dissolve the Company, such that the Company may remain listed on the OTC Markets and allow it to seek alternative opportunities, including potentially a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

These unsecured promissory notes were collectively known as Extension Loans. The Extension Loans were amended on May 10, 2023 to provide that the Extension Loans will be converted upon completion of a Business Combination into ordinary shares at a price of $10.10 per share.

The Sponsor has agreed to waive its rights to liquidating distributions from the Trust Account with respect to the Founder Shares it will receive if the Company fails to complete a Business Combination within the Combination Period. However, if the Sponsor or any of its respective affiliates acquire Public Shares, such Public Shares will be entitled to liquidating distributions from the Trust Account if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period, and in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the Initial Public Offering price per Unit ($10.00).

In order to protect the amounts held in the Trust Account, the Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company’s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below the lesser of (1) $10.10 per Public Share and (2) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.10 per Public Share, due to reductions in the value of trust assets, in each case net of the interest that may be withdrawn to pay taxes. This liability will not apply to any claims by a third party who executed a waiver of any and all rights to seek access to the Trust Account and as to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavouring to have all vendors, service providers (other than the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account.

F-8

On September 30, 2023, the Company executed that certain Agreement and Plan of Merger (the “Merger Agreement”), by and between the Company, KAC Merger Sub 1, a Cayman Islands exempted company and wholly owned subsidiary of the Company (“Purchaser”), KAC Merger Sub 2, a Cayman Islands exempted company and wholly owned subsidiary of Purchaser (“Merger Sub”), NR Instant Produce Public Company Limited, company formed under the laws of Thailand (“NRF” or the “Shareholder”), and Bamboo Mart Limited, a Cayman Islands exempted company (“Bamboo”).

On March 29, 2024, the Parties entered into an amendment no. 1 (the “Amendment”) to the Merger Agreement in accordance with the terms of the Merger Agreement. Under the Amendment, (i) the original provision of fairness opinion issuance date under section 4.2(a) was amended to no later than May 31, 2024; (ii) under section 4.2(b), the delivery date of the Parent Parties’ written due diligence request list to the Company was amended to no later than May 1, 2024 and the Company delivery date of the due diligence items based on the written due diligence request list was amended to no later than May 15, 2024; and (iii) the definition of “Outside Date” under section 12(d)(i) was amended to November 15, 2024.

On July 18, 2024, the parties agreed to amend the merger consideration to $188,000,000 with two portions of earn out payments.

In addition to the merger consideration of $188,000,000 to be received in connection with the Acquisition Merger, the Bamboo Shareholders have the right to receive “Earnout Consideration” (as defined in the A&R Merger Agreement) of up to 8,554,455 shares of the Purchaser Ordinary Shares. See Note 6 – Commitments and Contingencies – Business Combination Agreement.

On September 25, 2024, the Company entered into an amended and restated agreement and plan of merger (as it may be amended, supplemented, or otherwise modified from time to time, the “A&R Merger Agreement I”), by and among the Company, Purchaser, Merger Sub, the Principal Shareholders, and Bamboo Mart, pursuant to which (a) the Company will be merged with and into Purchaser (the “Reincorporation Merger”), with Purchaser surviving the Reincorporation Merger, and (b) Merger Sub will be merged with and into Bamboo Mart (the “Acquisition Merger”), with Bamboo Mart surviving the Acquisition Merger as a direct wholly owned subsidiary of Purchaser (collectively, the “Proposed Business Combination”). Following the Proposed Business Combination, Purchaser will be a publicly traded company. The closing of the Proposed Business Combination shall occur no later than March 31, 2025.

On December 14, 2024, the Company entered into an amended and restated agreement and plan of merger (as it may be amended, supplemented, or otherwise modified from time to time, the “A&R Merger Agreement II”), by and among the Company, Purchaser, Merger Sub, the Principal Shareholders, and Bamboo Mart, pursuant to which (a) the Company will be merged with and into Purchaser (the “Reincorporation Merger”), with Purchaser surviving the Reincorporation Merger, and (b) Merger Sub will be merged with and into Bamboo Mart (the “Acquisition Merger”), with Bamboo Mart surviving the Acquisition Merger as a direct wholly owned subsidiary of Purchaser (collectively, the “Proposed Business Combination”). Following the Proposed Business Combination, Purchaser will be a publicly traded company. The closing of the Proposed Business Combination shall occur no later than June 16, 2025.

F-9

Going Concern Considerations, Liquidity and Capital Resources

As of March 31, 2025, the Company had insufficient liquidity to meet its future obligations. As of March 31, 2025, the Company had working capital deficit of $4,358,737. The Company has an accumulated deficit and has not generated cash from operations to support its ongoing business plan. On May 16, 2025, the Company failed to properly extend the business combination period to June 16, 2025, as it did not deposit $50,000 to the trust account in order to extend the date by which it must consummate an initial business combination to beyond May 16, 2025. The Company is in process of liquidating the trust account and redeeming the Public Shares and the Business Combination is terminated. The Company expects to incur significant costs in connection with the liquidation of trust account. The board of directors of the Company intends to seek to amend the Charter to remove the obligation to liquidate and dissolve the Company, such that the Company may remain listed on the OTC Markets and allow it to seek alternative opportunities, including potentially a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

In connection with the Company’s assessment of going concern considerations in accordance with Accounting Standard Update (“ASU”) No. 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that its history of losses and insufficient liquidity raise substantial doubt about the ability to continue as a going concern. In addition to if the Company does not close the Business Combination by September 30, 2025, (as extended pursuant to A&R Merger Agreement dated May 9, 2025, 2025), the Company is required to cease all operations, redeem the public shares and thereafter liquidate and dissolve. The board of directors of the Company intends to seek to amend the Charter to remove the obligation to liquidate and dissolve the Company The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Risks and Uncertainties

The military action commenced in February 2022 by the Russian Federation and Belarus in the country of Ukraine and related economic sanctions, and a series of terror attacks commenced in October 2023 by Hamas militants and members of other terrorist organizations infiltrating Israel’s southern border from the Gaza Strip and the ensuing war between the State of Israel and Harakat al-Muqawama al-Islamiya (Islamic Resistance Movement) or “Hamas,” could trigger global geopolitical, trade, political, or sanctions risks, as well as the risk of regional or international expansion of the conflict, including isolated conflicts or terrorist attacks outside of the immediate conflict area, as a result of which the Company’s ability to consummate a Business Combination, or the operations of a target business with which the Company ultimately consummates a Business Combination, may be materially and adversely affected. In addition, the Company’s ability to consummate a transaction may be dependent on the ability to raise equity and debt financing which may be impacted by these events, including as a result of increased market volatility, or decreased market liquidity in third-party financing being unavailable on terms acceptable to the Company or at all. The impact of this action and related sanctions on the world economy and the specific impact on the Company’s financial position, results of operations and/or ability to consummate a Business Combination are not yet determinable.

F-10

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) and pursuant to the rules and regulations of the SEC.

Certain information and note disclosures normally included in the financial statements prepared in accordance with US GAAP have been condensed. As such, the information included in these financial statements should be read in conjunction with the audited financial statements as of June 30, 2024 filed with the SEC on Form 10-K. The accompanying condensed consolidated balance sheet as of June 30, 2024 has been derived from the audited consolidated financial statements included in that Form 10-K. In the opinion of the Company’s management, these condensed financial statements include all adjustments, which are only of a normal and recurring nature, necessary for a fair statement of the Company’s financial position as of March 31, 2025 and the Company’s results of operations and cash flows for the periods presented. The results of operations for the three and nine months ended March 31, 2025 are not necessarily indicative of the results to be expected for the full year ending June 30, 2025.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended (the “Securities Act”), as modified by the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

F-11

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had cash of $nil and $985 As of March 31, 2025 and June 30, 2024, respectively.

Cash held in Trust Account

As of March 31, 2025 and June 30, 2024, the Company had cash of $10,599,917 and $16,152,108 held in the Trust Account.

Offering Costs associated with the Initial Public Offering

The Company complies with the requirements of the Financial Accounting Standards Board (“FASB”) ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A, “Expenses of Offering.” Offering costs of $894,582 consisted principally of costs incurred in connection with preparation for the Initial Public Offering. These offering costs, together with the underwriter fees of $4,289,900 (or $1,559,900 paid in cash upon the closing of the Initial Public Offering and a deferred fee of $2,730,000), were charged to stockholders’ equity upon completion of the Initial Public Offering.

Ordinary shares subject to possible redemption

The Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance enumerated in ASC 480 “Distinguishing Liabilities from Equity”. Ordinary shares subject to mandatory redemption is classified as a liability instrument and is measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders’ equity. The Company’s ordinary shares feature certain redemption rights that are considered by the Company to be outside of the Company’s control and subject to the occurrence of uncertain future events.

During the year ended June 30, 2023, shareholders elected to redeem 5,710,184 ordinary shares for a total redemption amount of $58,312,401 withdrawn from the Trust Account.

On December 14, 2023, shareholders redeemed 752,053 ordinary shares for a total redemption amount of $8,621,702 withdrawn from the Trust Account.

On December 12, 2024, shareholders redeemed 518,968 ordinary shares for a total redemption amount of $6,502,636 withdrawn from the Trust Account.

Accordingly, As of March 31, 2025 and June 30, 2024, 818,795 and 1,337,763 ordinary shares were subject to possible redemption, respectively, in the amount of $10,599,917 and $16,152,108 are presented as temporary equity, outside of the shareholders’ deficit section of the Company’s balance sheets, respectively.

The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Immediately upon the closing of the Initial Public Offering, the Company recognized a measurement adjustment from initial book value to redemption amount value. The change in the carrying value of redeemable ordinary shares resulted in charges against additional paid-in capital and accumulated deficit.

F-12

As of March 31, 2025 and June 30, 2024, the ordinary shares reflected on the balance sheets is reconciled in the following table:

Gross proceeds	$	78,000,000
Less:
Transaction costs allocated to ordinary shares		(4,599,397	)
Proceeds allocated to Public Rights and Warrants		(8,275,800	)
Redemption of 5,710,184 ordinary shares		(58,312,401	)
Plus:
Remeasurement adjustment of carrying value to redemption value		15,989,837
Ordinary shares subject to possible redemption – June 30, 2023		22,802,239
Plus:
Redemption of 752,053 ordinary shares		(8,621,702	)
Remeasurement adjustment of carrying value to redemption value		1,971,571

Ordinary shares subject to possible redemption – June 30, 2024		16,152,108
Plus:
Redemption of 518,968 ordinary shares		(6,502,636	)
Remeasurement adjustment of carrying value to redemption value		950,445
Ordinary shares subject to possible redemption – March 31, 2025	$	10,599,917

Warrants

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own ordinary shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. The Company determined that upon further review of the warrant agreements, the Company concluded that its warrants qualify for equity accounting treatment.

Income Taxes

The Company follows the asset and liability method of accounting for income taxes under ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties As of March 31, 2025 and June 30, 2024. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

F-13

The Company may be subject to potential examination by foreign taxing authorities in the area of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with foreign tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.

The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the other tax jurisdictions. Consequently, income taxes are not reflected in the Company’s financial statements.

Net Income (Loss) per Ordinary Share

The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net income (loss) per ordinary share is computed by dividing net income (loss) by the weighted average number of ordinary shares outstanding for the period. The Company applies the two-class method in calculating earnings per share. The remeasurement adjustment associated with the redeemable ordinary shares is excluded from earnings (loss) per share as the redemption value approximates fair value.

The calculation of diluted income per ordinary share does not consider the effect of the warrants and rights issued in connection with the (i) Initial Public Offering and (ii) the Private Placement. For the three and nine months ended March 31, 2024 and 2023, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted income (loss) per share is the same as basic income (loss) per share for the period presented.

The following table reflects the calculation of basic and diluted net income (loss) per ordinary share.

SCHEDULE OF NET INCOME (LOSS) PER SHARE

	Redeemable Ordinary Shares			Non-Redeemable Ordinary Shares			Redeemable Ordinary Shares		Non-Redeemable Ordinary Shares
	For the Three Months Ended March 31, 2025						For the Three Months Ended March 31, 2024
	Redeemable Ordinary Shares			Non-Redeemable Ordinary Shares			Redeemable Ordinary Shares		Non-Redeemable Ordinary Shares
Numerator: Allocation of net (loss) income, as adjusted	$	(15,550	)	$	(44,556	)	$	16,902	$	29,642
Denominator: Basic and diluted weighted average shares outstanding		818,795			2,346,143			1,337,763		2,346,143
Basic and diluted net (loss) income per ordinary share	$	(0.02	)	$	(0.02	)	$	0.01	$	0.01

	Redeemable Ordinary Shares			Non-Redeemable Ordinary Shares			Redeemable Ordinary Shares		Non-Redeemable Ordinary Shares
	For the Nine Months Ended March 31, 2025						For the Nine Months Ended March 31, 2024
	Redeemable Ordinary Shares			Non-Redeemable Ordinary Shares			Redeemable Ordinary Shares		Non-Redeemable Ordinary Shares
Numerator: Allocation of net (loss) income, as adjusted	$	(88,637	)	$	(183,818	)	$	30,277	$	39,586
Denominator: Basic and diluted weighted average shares outstanding		1,131,312			2,346,143			1,794,464		2,346,143
Basic and diluted net (loss) income per ordinary share	$	(0.08	)	$	(0.08	)	$	0.02	$	0.02

F-14

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on this account. The Company has not experienced any losses on the Trust Account.

Fair Value of Financial Instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC 820, “Fair Value Measurement,” approximates the carrying amounts represented in the balance sheet, primarily due to their short-term nature. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

Level 1 Inputs: Unadjusted quoted prices for identical assets or instruments in active markets.

Level 2 Inputs: Quoted prices for similar instruments in active markets and quoted prices for identical or similar instruments in markets that are not active and model derived valuations whose inputs are observable or whose significant value drivers are observable.

Level 3 Inputs: Significant inputs into the valuation model are unobservable.

The Company does not have any recurring Level 2 or Level 3 assets or liabilities. The carrying value of the Company’s financial instruments including its cash and accrued liabilities approximate their fair values principally because of their short-term nature.

As of March 31, 2025 and June 30, 2024, the Company’s portfolio of investments held in the Trust Account is comprised of cash held in trust account.

Share-Based Compensation

The Company accounts for share-based compensation in accordance with ASC Topic 718, “Compensation—Stock Compensation” (“ASC 718”), which establishes financial accounting and reporting standards for share-based employee compensation. It defines a fair value-based method of accounting for an employee stock option or similar equity instrument.

The Company recognizes all forms of share-based payments, including stock option grants, warrants and restricted stock grants, at their fair value on the grant date, which are based on the estimated number of awards that are ultimately expected to vest.

Share-based compensation expenses are included in general and administrative expenses in the statements of operations. Share-based payments issued to placement agents are classified as a direct cost of a share offering and are recorded as a reduction in additional paid in capital.

F-15

Recent Accounting Standards

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires the disclosure of additional segment information. ASU No. 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company expects that adopting ASU 2023-07 will not have a material impact on its financial position, results of operations or cash flows.

On December 14, 2023, the FASB issued a final standard on improvements to income tax disclosures. The standard requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. ASU 2023-09, Improvements to Income Tax Disclosures, applies to all entities subject to income taxes. For public business entities (PBEs), the new requirements will be effective for annual periods beginning after December 15, 2024. For entities other than public business entities (non-PBEs), the requirements will be effective for annual periods beginning after December 15, 2025. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently assessing the impact, if any, that ASU 2023-09 would have on its financial position, results of operations or cash flows.

Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on our financial statements.

NOTE 3 — INITIAL PUBLIC OFFERING

Pursuant to the Initial Public Offering, the Company sold 7,500,000 Units at a purchase price of $10.00 per Unit generating gross proceeds to the Company in the amount of $75,000,000. Each Unit will consist of one ordinary share, one half of one redeemable warrant (“Public Warrant”) and one right to receive one-tenth (1/10) of an ordinary share upon the consummation of an initial business combination. Each whole Public Warrant will entitle the holder to purchase one ordinary share at a price of $11.50 per share subject to adjustment (see Note 7). Each ten rights entitle the holder thereof to receive one ordinary share at the closing of a business combination. The Company will not issue fractional shares. As a result, shareholders must hold rights in multiples of 10 in order to receive shares for all of the rights upon closing of a business combination. On December 16, 2021, the underwriters partially exercised the over-allotment option by purchasing 300,000 additional units, generating $3,000,000.

NOTE 4 — PRIVATE PLACEMENTS

Simultaneously with the closing of the Initial Public Offering, the Company consummated the private sale (the “Private Placement”) of an aggregate of 348,143 Units (the “Private Placement Units”) at a purchase price of $10.00 per Private Placement Unit, generating gross proceeds to the Company in the amount of $3,481,430. On December 16, 2021, the underwriters partially exercised the option at which time the Sponsor purchased 9,000 additional units, generating $90,000.

A portion of the proceeds from the Private Placement Units was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the proceeds from the sale of the Private Placement Units held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law). The Private Placement Units will not be transferable, assignable or saleable until 30 days after the completion of an Initial Business Combination, subject to certain exceptions.

F-16

NOTE 5 — RELATED PARTIES

Founder Shares

On May 13 and October 21, 2021, the Sponsor received an aggregate of 2,156,250 of the Company’s ordinary shares (the “Founder Shares”) in exchange for a capital contribution of $25,000 that was paid by the Sponsor for deferred offering costs. All share amounts have been retroactively restated to reflect this number of Founder Shares. The Founder Shares included an aggregate of up to 281,250 shares subject to forfeiture to the extent that the underwriters’ over-allotment is not exercised in full or in part, so that the number of Founder Shares will equal, on an as-converted basis, approximately 20% of the Company’s issued and outstanding ordinary shares after the Initial Public Offering. Due to the partial exercise of the over-allotment option by the underwriters, these 75,000 shares are no longer subject to forfeiture.

The Sponsor has agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to occur of: (A) six months after the completion of a Business Combination or (B) the date of the consummation of our initial business combination, and subsequently, we consummate a liquidation, merger, stock exchange or other similar transaction which results in all of our shareholders having the right to exchange their ordinary shares for cash, securities or other property or (C) after 150 calendar days after the date of the consummation of our initial business combination, and subsequently, the closing price of our ordinary shares equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period.

General and Administrative Services

Commencing on the date the Units are first listed on the Nasdaq, the Company has agreed to pay the Sponsor a total of $5,000 per month for office space, utilities and secretarial and administrative support during the Combination Period. Upon the earlier of the completion of the Initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. Effective on January 1, 2024, the Company and the Sponsor agreed to terminate the management services.

During the three months ended March 31, 2025 and 2024, the Company did not record management fees. During the nine months ended March 31, 2025 and 2024, the Company recorded $nil and $30,000 in management fees, respectively.

On January 1, 2024, the Company has agreed to pay NR Instant Produce PCL (“NRIP”) (a parent company of the Sponsor Shareholder) a total of $5,000 per month for office space, utilities and secretarial and administrative support during the Combination Period. For the three months ended March 31, 2025 and 2024, the Company recorded $15,000 and $15,000 in management fees, respectively. For the nine months ended March 31, 2025 and 2024, the Company recorded $45,000 and $15,000 in management fees, respectively. From January 1, 2024 through March 31, 2025, the Company did not pay management fees to NRIP. As of March 31, 2025 and June 30, 2024, the Company had management fees payable of $75,000 and $30,000, respectively, due to the NRIP.

F-17

Working Capital Note

On April 23, 2021, the Sponsor issued an unsecured promissory note to the Company (the “Working Capital Note”), pursuant to which the Company may borrow up to an aggregate principal amount of $200,000. On May 12, 2021, the amount of the Working Capital Note was increased to $1,000,000. On December 10, 2021, the Sponsor agreed to provide an extension to the maturity date of the Working Capital Note. The Working Capital Note is non-interest bearing and payable on the earlier of (i) July 30, 2023 or (ii) the consummation of the Initial Business Combination. The Working Capital Note was amended on May 10, 2023 to provide that the Working Capital Note shall be payable on the earlier of: (i) July 30, 2023 or (ii) the date on which the Company consummates the initial business combination, by conversion of the Working Capital Note into ordinary shares of the Company concurrently with the closing of a business combination at a price of $10.10 per share. The Working Capital Note was further amended on September 18, 2023 to provide that the Working Capital Note shall be payable on the earlier of: (i) December 16, 2023 or (ii) the date on which the Company consummates the initial business combination, by conversion of the Working Capital Note into ordinary shares of the Company concurrently with the closing of a business combination at a price of $10.10 per share. On October 25, 2023, the Company and the Sponsor entered into another amendment to the Working Capital Note to increase the principal amount of the Working Capital Note from $1,000,000 to $2,000,000. On February 27, 2024 , the Working Capital Note was amended to provide that the Working Capital Note shall be payable on the earlier of: (i) September 30, 2025 (as extended pursuant to A&R Merger Agreement dated May 9, 2025) or (ii) the date on which the Company consummates the initial business combination, by conversion of the Working Capital Note into ordinary shares of the Company concurrently with the closing of a business combination at a price of $10.10 per share.

As of March 31, 2025 and June 30, 2024, there was $1,375,341 and $1,111,370 outstanding under the Working Capital Note, respectively.

Extension Loans

In order to finance transaction costs in connection with extending time to complete a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Extension Loans”). Such Extension Loans would be evidenced by promissory notes. The notes will be converted upon completion of a Business Combination into ordinary shares at a price of $10.10 per share. On December 14, 2022 and March 10, 2023, the Company issued two non-interest bearing unsecured promissory notes, each in an amount of $360,000, to the Sponsor in exchange for Sponsor depositing such amount into the Company’s trust account in order to extend the amount of time it has available to complete a business combination until June 16, 2023.

The Extension Loans was amended on May 10, 2023 to provide that the Extension Loans will be converted upon completion of a Business Combination into ordinary shares at a price of $10.10 per share.

From June 9, 2023 through November 10, 2023, the Company entered into six unsecured promissory note arrangements with the Sponsor, each in an amount of $120,000, in exchange for Sponsor depositing such amount into the Company’s trust account in order to extend the amount of time it has available to complete a business combination until December 16, 2023. The Sponsor deposited such amount into the Company’s trust account.

F-18

On May 16, 2025, the Company failed to properly extend the business combination period to June 16, 2025, as it did not deposit $50,000 to the trust account in order to extend the date by which it must consummate an initial business combination (the “Termination Date”) to beyond May 16, 2025. Under the Company’s Fourth Amended and Restated Memorandum and Articles of Association (the “Charter”), if the Company does not consummate an initial business combination by the Termination Date, the Company is required to (i) immediately commence a wind down of operations, (ii) as promptly as reasonably possible but not more than ten business days thereafter, liquidate the Trust Account and redeem all of the outstanding public ordinary shares (“Public Shares”) that were included in the units issued in its initial public offering, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining members and the directors, liquidate and dissolve.

On May 9, 2025, the Company entered into an amended and restated agreement and plan of merger (as it may be amended, supplemented, or otherwise modified from time to time, the “A&R Merger Agreement III”), by and among the Company, Purchaser, Merger Sub, the Principal Shareholders, and Bamboo Mart, pursuant to which (a) the Company will be merged with and into Purchaser (the “Reincorporation Merger”), with Purchaser surviving the Reincorporation Merger, and (b) Merger Sub will be merged with and into Bamboo Mart (the “Acquisition Merger”), with Bamboo Mart surviving the Acquisition Merger as a direct wholly owned subsidiary of Purchaser (collectively, the “Proposed Business Combination”). Following the Proposed Business Combination, Purchaser will be a publicly traded company. The closing of the Proposed Business Combination shall occur no later than September 30, 2025. On May 16, 2025, the Company failed to properly extend the business combination period to June 16, 2025, as it did not deposit $50,000 to the trust account in order to extend the date by which it must consummate an initial business combination (the “Termination Date”) to beyond May 16, 2025. The Company is in process of liquidating the trust account and redeeming the Public Shares and the Business Combination is terminated.

As of March 31, 2025 and June 30, 2024, there were $2,240,000 and $1,790,000 outstanding under the Extension Loans.

NOTE 6 — COMMITMENTS AND CONTINGENCIES

Registration Rights

The holders of the founder shares, Private Placement Units, shares being issued to the underwriters of the Initial Public Offering, and units that may be issued on conversion of Extension Loans and Working Capital Note (and in each case holders of their component securities, as applicable) will be entitled to registration rights pursuant to a registration rights agreement to be signed prior to or on the effective date of Initial Public Offering requiring the Company to register such securities for resale. The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until the securities covered thereby are released from their lock-up restrictions. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

F-19

Underwriting Agreement

The Company granted the underwriters a 45-day option from the date of Initial Public Offering to purchase up to 1,125,000 additional Units to cover over-allotments, if any, at the Initial Public Offering price less the underwriting discounts. On December 16, 2021, the underwriters partially exercised the over-allotment option by purchasing 300,000 additional units, generating $3,000,000.

The underwriters were paid to a cash underwriting discount of $0.20 per Unit, or $1,500,000 in the aggregate (or $1,725,000 in the aggregate if the underwriters’ over-allotment option is exercised in full), payable upon the closing of the Initial Public Offering. In addition, the underwriters will be entitled to a deferred fee of $0.35 per Unit, or $2,625,000 in the aggregate (or $3,018,750 in the aggregate if the underwriters’ over-allotment option is exercised in full). The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. Upon partial exercise of the over-allotment option, the Company paid the underwriters an additional fee of $59,900 (net of Representative’s purchase option fee of $100) and an additional deferred fee of $105,000 which will be payable upon completion of a Business Combination.

The underwriters were also issued 39,000 Ordinary shares as representative shares, in connection with the IPO. Upon close of the Initial Public Offering, the Company recorded additional issuance costs of $341,230, the grant date fair value of the shares, with an offset to additional paid-in capital.

On December 8, 2022, the Company and the underwriters in the IPO, entered into an amendment of the underwriting agreement (the “UWA Amendment”). The UWA Amendment provides that the $2,730,000 deferred underwriting fee from the IPO (the “Deferred Underwriting Fee”) shall be paid as follows: (a) to the extent that the balance in the Company’s trust account (the “Trust Account”) as of the Closing Date exceeds $2,000,000, such excess shall be applied to the payment of the Deferred Underwriting Fee in cash up to $2,730,000, and (b) any amounts not so paid pursuant to the preceding clause (a) shall be converted into Purchaser ordinary shares at a conversion rate of $10.00 per share.

The Company is in the process of liquidating the Trust Account and redeeming the Public Shares. The deferred underwriting fee will be not reversed until the Trust Account is liquidated.

Advisory Agreement

On June 14, 2023, the Company entered into a letter agreement with Chardan Capital Markets, LLC (“Chardan”) in which the company retains Chardan to provide financial advisory services including (i) advise and assist the Company in negotiating the terms and conditions in the business combination, (ii) introduce the Company to potential targets, takeover candidates, investors and/or business partners, (iii) perform other financial advisory services as agreed upon, and (iv) engage additional broke-dealers upon the Company’s written consent. As compensation for such services, the Company is to pay Chardan advisory fees which become payable upon the consummation of the business combination. The advisory fee is the greater of (a) $2,000,000 and (b) the total of 3% of the first $100 million of merger consideration, 2% of the merger consideration between $100 million and $200 million, and 1% of the merger consideration exceeding $200 million.

Because the consummation of the business combination is contingent and is not in the control of the Company, the Company cannot reasonably assess if the liabilities due to Chardan will incur. Accordingly, the Company does not accrue expenses due to Chardan until the consummation of the business combination.

Business Combination Agreement

On September 30, 2023, the Company executed and amended Merger Agreements with Bamboo for merger consideration of $188,000,000. For details, please refer to Note 1.

In addition to the merger consideration to $188,000,000 to be received in connection with the Acquisition Merger, the Bamboo Shareholders have the right to receive “Earnout Consideration” (as defined in the A&R Merger Agreement) of up to 8,554,455 shares of the Purchaser Ordinary Shares as follows:

F-20

Number of Purchaser Ordinary Shares to be Received		Condition to be Satisfied
Up to 2,930,693 Purchaser Ordinary Shares		(i) if the volume-weighted average price (“VWAP”) is equal to or greater than $12.50 per share for any 20 out of 30 consecutive trading days within three years after the Closing Date, Purchaser shall issue to the Bamboo Shareholders 1,099,010 Purchaser Ordinary Shares;
		(ii) if the VWAP is equal to or greater than $15.00 per share for any 20 out of 30 consecutive trading days within three years after the Closing Date, in addition to the issuance of the Earnout Shares set forth in subparagraph (i) above, Purchaser shall issue to the Bamboo Shareholders 1,099,010 Purchaser Ordinary Shares; and

		(iii) if the VWAP is equal to or greater than $17.50 per share for any 20 out of 30 consecutive trading days within three years after the Closing Date, in addition to the issuance of the Earnout Shares set forth in subparagraphs (i) and (ii) above, Purchaser shall issue to the Bamboo Shareholders 732,673 Purchaser Ordinary Shares.

Up to 5,623,762 Purchaser Ordinary Shares		(i) if the revenue of the Bamboo Group for the fiscal year commencing from January 1, 2025 and ending on December 31, 2025 equals or exceeds $122,800,000, Purchaser shall issue to the Bamboo Shareholders 2,811,881 Purchaser Ordinary Shares; and

		(ii) if the revenue of the Bamboo Group for the fiscal year commencing from January 1, 2026 and ending on December 31, 2026 equals or exceeds $170,200,000, in addition to the issuance of the Tranche 2 Earnout Shares set forth in subparagraph (i) above, Purchaser shall issue to the Bamboo Shareholders 2,811,881 Purchaser Ordinary Shares.

As previously disclosed, pursuant to the terms of a Share Purchase Agreement (“SPA”) dated June 30, 2023, by and among Kairous Ventures Limited (“KVL”), and Regeneration Capital (Cayman) Limited (the “Buyer” ), KVL agreed to sell to Buyer, and Buyer agreed to purchase from KVL, an aggregate of 49 ordinary shares, representing a 49% equity interest in, Kairous Asia Limited, which is the Company’s sponsor (the “Sponsor”) for an aggregate purchase price of $1,486,504 (the “Transaction”). In addition, KVL also offered the Buyer a 30-day call option to purchase the remaining 51% equity interest in the Sponsor at cash consideration of approximately $1.1 million. The Transaction was consummated on July 14, 2023, and the Buyer did not exercise the call option before it expired.

The Company analyzed the SPA entered into in June 2023 under SAB Topic 5, Miscellaneous Accounting, section T, Accounting for Expenses or Liabilities Paid by Principal Stockholder(s). Because the sum of the fair value of 49% equity interest in the Sponsor KVL transferred and the fair value of 30-day call option offered was below the cash consideration of $1.49 million, the Company did not record expense under SAB Topic 5T.

The Buyer and Bamboo Mart Limited are under the common control of NRIP. Mr. Dhas Udomdhammabhakdi was appointed as an independent director and chairman of the Audit Committee of Kairous Acquisition Corp. Limited on November 25, 2023. He has served as an independent director since 2018 and as Chairman of risk management committee since 2021 of the board of NRIP.

F-21

On September 15, 2023, the Buyer and KVL entered into a loan facility agreement in the amount of up to $1,300,000 (the “Facility Agreement”). The loan bears interest at 6.5% per annum. KVL has drawn down the full $1,300,000 of this facility. On September 15, 2023, the Buyer and KVL entered into an Equitable Share Mortgage Agreement (the “Share Mortgage”), pursuant to which KVL mortgaged the 51% equity interest in the Sponsor to and for the benefit of the Buyer, as security for KVL’s obligation under the Facility Agreement (the “Mortgaged Shares”). KVL retained all rights to vote the Mortgaged Shares unless and until an event of default under the Facility Agreement and/or the Share Mortgage occurs.

On September 25, 2024, the Buyer issued a demand notice to KVL, notifying KVL that it had not repaid the loan or any other amounts due and payable under the terms of the Facility Agreement, and requesting repayment of $1,384,331 (representing the loan together with interest and default interest thereon accrued up to September 23, 2024) by no later than September 30, 2024, failing which the Buyer intended to enforce the Share Mortgage over the Mortgaged Shares. On November 1, 2024, the Buyer took legal title of the Mortgaged Shares from KVL, and became the record and beneficial owner of 100% of the Sponsor. The Company analyzed the settlement of $1,384,331 between KVL and the Buyer under SAB Topic 5, Miscellaneous Accounting, section T, Accounting for Expenses or Liabilities Paid by Principal Stockholder(s) and concluded that such settlement provides the Company with a benefit in the form of the right to receive additional extension contributions from the Buyer. However, KVL transferred the equity interest at premium and the Company did not record expense under SAB Topic 5T.

On August 23, 2024, the Buyer entered into a share purchase agreement (the “SPA 2024”) with Mr. Oran Vongsuraphichet, an unrelated third party with the Buyer and KACL. Pursuant to the SPA 2024, the Buyer agreed to sell to Mr. Oran, and Mr. Oran agreed to purchase from the Buyer for an aggregate of 166,667 ordinary shares, representing a 7.2% equity interest in KAL, for an aggregate purchase price of $300,000. The issuance of share is to raise fund to support the operating activities of the Company. In the event that KACL is unable to complete a listing on NASDAQ, Mr. Oran has the put option to sell the shares back to the Buyer at $312,370. The transaction was closed on December 13, 2024. The Company analyzed the SPA 2024 under SAB Topic 5, Miscellaneous Accounting, section T, Accounting for Expenses or Liabilities Paid by Principal Stockholder(s) and concluded that the SPA 2024 provides the Company with a benefit in the form of the right to receive additional extension contributions from the new investor. However the Buyer sold 7.2% equity interest at premium and the Company did not record expense under SAB Topic 5T.

On September 17, 2024, the Buyer entered into a share purchase agreement (the “SPA 2024”) with Ms. Benyapa Rungruangnavarat, an unrelated third party with the Buyer and KACL. Pursuant to the SPA 2024, the Buyer agreed to sell to Ms. Benyapa, and Ms. Benyapa agreed to purchase from the Buyer for an aggregate of 783,000 ordinary shares, representing a 33.9% equity interest in KAL, for an aggregate purchase price of $1,200,000. The issuance of share is to raise fund to support the operating activities of the Company. The transaction was closed on February 20, 2025. The Company analyzed the SPA 2024 under SAB Topic 5, Miscellaneous Accounting, section T, Accounting for Expenses or Liabilities Paid by Principal Stockholder(s) and concluded that the SPA 2024 provides the Company with a benefit in the form of the right to receive additional extension contributions from the new investor. However the Buyer sold 33.9% equity interest at premium and the Company did not record expense under SAB Topic 5T. On June 24, 2025, the Buyer and Ms. Benyapa entered into a share repurchase agreement, pursuant to which the Company repurchased the 783,000 ordinary shares in KAL at cash consideration of THB 183,490,000 (equivalent to $6.1 million). The repurchase transaction is guaranteed by NRF. As of the date of this report, the repurchase has not closed.

F-22

NOTE 7 — SHAREHOLDERS’ EQUITY

Ordinary Shares — The Company is authorized to issue 500,000,000 ordinary shares with a par value of $0.0001 per share. Holders of ordinary shares are entitled to one vote for each share. As of March 31, 2025 and June 30, 2024, there were 2,346,143 ordinary shares issued and outstanding in shareholders’ equity. As of March 31, 2025 and June 30, 2024, there were an additional 818,795 and 1,337,763 ordinary shares included in temporary equity on the balance sheets, respectively.

Holders of ordinary shares will vote together as a single class on all matters submitted to a vote of our shareholders except as otherwise required by law. In connection with our initial business combination, we may enter into a shareholders agreement or other arrangements with the shareholders of the target or other investors to provide or voting or other corporate governance arrangements that differ from those in effect upon completion of the IPO.

Rights — Except in cases where the Company is not the surviving company in a business combination, each holder of a right will automatically receive one-tenth (1/10) of one ordinary share upon consummation of the initial business combination. The Company will not issue fractional shares in connection with an exchange of rights. Fractional shares will either be rounded down to the nearest whole share or otherwise addressed in accordance with the applicable provisions of Cayman law.

Warrants —Each whole warrant entitles the registered holder to purchase one share of ordinary share at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing 30 days after the completion of an initial business combination. However, no warrants will be exercisable for cash unless the Company has an effective and current registration statement covering the ordinary shares issuable upon exercise of the warrants and a current Form 10-Q relating to such ordinary shares. Notwithstanding the foregoing, if a registration statement covering the ordinary shares issuable upon exercise of the public warrants is not effective by the 90th day following the consummation of the initial business combination, warrant holders may, until such time as there is an effective registration statement and during any period when we shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the Securities Act, provided that such exemption is available. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis. In the event of such cashless exercise, each holder would pay the exercise price by surrendering the warrants for that number of ordinary shares equal to the quotient obtained by dividing (x) the product of the number of ordinary shares underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” for this purpose will mean the average reported last sale price of the ordinary shares for the 10 trading days ending on the third trading day prior to the date of exercise. The warrants will expire on the fifth anniversary of our completion of an initial business combination or earlier upon redemption or liquidation.

The private warrants, as well as any warrants underlying additional units the Company issued to the Sponsor, officers, directors, initial shareholders or their affiliates in payment of working capital loans made to the Company, will be identical to the warrants underlying the units being offered.

The Company may call the warrants for redemption, in whole and not in part, at a price of $0.01 per warrant,

	●	at any time after the warrants become exercisable,
	●	upon not less than 30 days’ prior written notice of redemption to each warrant holder,
	●	if, and only if, the reported last sale price of the ordinary shares equals or exceeds $16.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30-trading day period commencing at any time after the warrants become exercisable and ending on the third business day prior to the notice of redemption to warrant holders; and
	●	if, and only if, there is a current registration statement in effect with respect to the ordinary shares underlying such warrants.

F-23

The right to exercise will be forfeited unless the warrants are exercised prior to the date specified in the notice of redemption. On and after the redemption date, a record holder of a warrant will have no further rights except to receive the redemption price for such holder’s warrant upon surrender of such warrant.

The redemption criteria for our warrants have been established at a price which is intended to provide warrant holders a reasonable premium to the initial exercise price and provide a sufficient differential between the then- prevailing share price and the warrant exercise price so that if the share price declines as a result of our redemption call, the redemption will not cause the share price to drop below the exercise price of the warrants.

If the Company calls the warrants for redemption as described above, management will have the option to require all holders that wish to exercise warrants to do so on a “cashless basis.” In such event, each holder would pay the exercise price by surrendering the warrants for that number of ordinary shares equal to the quotient obtained by dividing (x) the product of the number of ordinary shares underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” for this purpose shall mean the average reported last sale price of the ordinary shares for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants.

The warrants will be issued in registered form under a warrant agreement between Continental Stock Transfer & Trust Company, as warrant agent, and us. The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder (i) to cure any ambiguity or correct any mistake, including to conform the provisions of the warrant agreement to the description of the terms of the warrants and the warrant agreement set forth in the Prospectus, or to cure, correct or supplement any defective provision, or (ii) to add or change any other provisions with respect to matters or questions arising under the warrant agreement as the parties to the warrant agreement may deem necessary or desirable and that the parties deem to not adversely affect the interests of the registered holders of the warrants, but requires the approval, by written consent or vote, of the holders of at least 50% of the then outstanding public warrants in order to make any change that adversely affects the interests of the registered holders.

The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price, by certified or official bank check payable to us, for the number of warrants being exercised. The warrant holders do not have the rights or privileges of holders of ordinary shares and any voting rights until they exercise their warrants and receive ordinary shares. After the issuance of ordinary shares upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by shareholders.

Warrant holders may elect to be subject to a restriction on the exercise of their warrants such that an electing warrant holder would not be able to exercise their warrants to the extent that, after giving effect to such exercise, such holder would beneficially own in excess of 9.8% of the ordinary shares outstanding.

No fractional shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest in a share, the Company will, upon exercise, round up to the nearest whole number the number of ordinary shares to be issued to the warrant holder.

NOTE 8 — SUBSEQUENT EVENTS

On March 14, 2025 and April 16, 2025, the Company issued two unsecured promissory notes (“Notes”), each in the principal amount of $50,000, to the Sponsor in exchange for Sponsor depositing such amounts into the Company’s trust account in order to extend the business combination period to May 16, 2025. The Notes do not bear interest and mature upon the closing of a business combination by the Company. In addition, the Notes will be converted by the holder into ordinary shares of the Company at a price of $10.10 per share at the closing of a business combination.

On June 24, 2025, the Buyer and Ms. Benyapa entered into a share repurchase agreement, pursuant to which the Company repurchased the 783,000 ordinary shares in KAL at cash consideration of THB 183,490,000 (equivalent to $6.1 million). The repurchase transaction is guaranteed by NRF. See Note 6.

The Company evaluated subsequent events and transactions that occurred after the balance sheet date through the date that the financial statements were issued. Based upon this review, the Company did not identify any other subsequent events that would have required adjustment or disclosure in the financial statements.

F-24

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

References in this report (the “Quarterly Report”) to “we,” “us” or the “Company” refer to Kairous Acquisition Corp. Limited. References to our “management” or our “management team” refer to our officers and directors, and references to the “Sponsor” refer to Kairous Asia Limited. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and the notes thereto contained elsewhere in this Quarterly Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Overview

We are a blank check company, incorporated on March 24, 2021, as a Cayman Islands exempted company. We were incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this Quarterly Report as our “initial business combination”. We intend to effectuate our initial business combination using cash from the proceeds of our initial public offering (the “Initial Public Offering”) and the private placement of the Private Placement Units (as defined below), the sale of certain forward purchase securities, our shares (other backstop agreements we may enter into following the consummation of the Initial Public Offering or otherwise), securities, debt or a combination of cash, equity and debt.

We held our annual meeting of shareholders on December 2, 2022 (the “2022 Annual Meeting”). During the 2022 Annual Meeting, shareholders approved, among other things, (x) the Amended and Restated Memorandum and Articles of Association to extend the date by which the Company has the right to extend the time to complete a business combination eight (8) times, as follows: (i) two (2) times for an additional three (3) months each time from December 16, 2022 to June 16, 2023 for each three-month extension, followed by (ii) six (6) times for an additional one (1) month each time from June 16, 2023 to December 16, 2023 for each one-month extension; (y) an amendment to the Company’s investment management trust agreement, dated December 13, 2021, by and between the Company and Continental Stock Transfer & Trust Company to extend the time to complete a business combination eight (8) times, as follows: (i) two (2) times for an additional three (3) months each time from December 16, 2022 to June 16, 2023 by depositing $360,000 to the trust account for each three-month extension, followed by (ii) six (6) times for an additional one (1) month each time from June 16, 2023 to December 16, 2023 by depositing $120,000 to the trust account for each one-month extension; and (z) elected all of the six nominees for directors to serve until the next annual meeting of shareholders approved.

On September 25, 2024, the Company entered into an amended and restated agreement and plan of merger (as it may be amended, supplemented, or otherwise modified from time to time, the “A&R Merger Agreement”), by and among the Company, Purchaser, Merger Sub, the Principal Shareholders, and Bamboo Mart, pursuant to which (a) the Company will be merged with and into Purchaser (the “Reincorporation Merger”), with Purchaser surviving the Reincorporation Merger, and (b) Merger Sub will be merged with and into Bamboo Mart (the “Acquisition Merger”), with Bamboo Mart surviving the Acquisition Merger as a direct wholly owned subsidiary of Purchaser (collectively, the “Proposed Business Combination”). Following the Proposed Business Combination, Purchaser will be a publicly traded company. The closing of the Proposed Business Combination shall occur no later than March 31, 2025.

On December 14, 2022, we issued an unsecured promissory note, in an amount of $360,000 (the “Extension Note No.1”) to Kairous Asia Limited, the Company’s initial public offering sponsor (“Sponsor”) in exchange for Sponsor depositing such amount into the Company’s trust account in order to extend the amount of time it has available to complete a business combination until March 16, 2023. On March 10, 2023, we issued an unsecured promissory note, in an amount of $360,000 to the Sponsor (the “Extension Note No.2”, together with Extension Note No.1, the “Extension Notes”) in exchange for Sponsor depositing such amount into the Company’s trust account in order to further extend the amount of time it has available to complete a business combination until June 16, 2023. The March Note may be converted, at the lender’s discretion, into additional ordinary shares. The Extension Notes were amended on May 10, 2023 to provide that the each of the Extension Notes will be converted upon completion of a Business Combination into the Company’s ordinary shares at a price of $10.10 per share. In the event that a Business Combination does not close by June 16, 2023, as such deadline may be further extended, the Extension Notes shall be deemed to be terminated and no amounts will thereafter be due thereon.

As approved by our shareholders at the Annual Meeting of Shareholders on December 14, 2023, we entered into an amendment, dated December 15, 2023 (the “Trust Amendment”) to the investment management trust agreement, dated December 13, 2021, as amended on December 7, 2022, with Continental Stock Transfer & Trust Company. Pursuant to the Trust Amendment, the Company has the right to extend the time to complete a business combination twelve (12) times for an additional one (1) month each time from December 16, 2023 to December 16, 2024 by depositing into the trust account $50,000 for each one-month extension. On December 15, 2023 through November 16, 2024, the Company issued 12 unsecured promissory notes, each in an amount of $50,000, to the Sponsor in exchange for Sponsor depositing such amount into the Company’s trust account in order to extend the amount of time it has available to complete a business combination until December 16, 2024.

As further approved by our shareholders at the Annual Meeting of Shareholders on December 6, 2024, we entered into an amendment, dated December 16, 2024 (the “Trust Amendment”) to the investment management trust agreement, dated December 13, 2021, as amended on December 7, 2022 and December 15, 2023, with Continental Stock Transfer & Trust Company. Pursuant to the Trust Amendment, the Company has the right to extend the time to complete a business combination six (6) times for an additional one (1) month each time from December 16, 2024 to June 16, 2025 by depositing into the trust account $50,000 for each one-month extension. On December 16, 2024 through April, 2025, the Company issued five unsecured promissory notes, each in an amount of $50,000, to the Sponsor in exchange for Sponsor depositing such amount into the Company’s trust account in order to extend the amount of time it has available to complete a business combination until May 16, 2025. On May 16, 2025, the Company failed to properly extend the business combination period to June 16, 2025, as it did not deposit $50,000 to the trust account in order to extend the date by which it must consummate an initial business combination (the “Termination Date”) to beyond May 16, 2025. Under the Company’s Fourth Amended and Restated Memorandum and Articles of Association (the “Charter”), if the Company does not consummate an initial business combination by the Termination Date, the Company is required to (i) immediately commence a wind down of operations, (ii) as promptly as reasonably possible but not more than ten business days thereafter, liquidate the Trust Account and redeem all of the outstanding public ordinary shares (“Public Shares”) that were included in the units issued in its initial public offering, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining members and the directors, liquidate and dissolve.

Business Combination Agreement

On December 9, 2022, we entered into that certain Agreement and Plan of Merger with, among others, Wellous Group Limited, a Cayman Islands exempted company (“Wellous”), which provides for a business combination between us and Wellous. Wellous is a fast-growing Asia-based international nutrition company that develops, manufactures, markets and sells health and wellness products. Subsequently on June 22, 2023, we and Wellous entered into a termination agreement which provides for the mutual termination of the Agreement and Plan of Merger.

On September 30, 2023, we entered into that certain Agreement and Plan of Merger (the “Original Merger Agreement”) with KAC Merger Sub 1, a Cayman Islands exempted company and our wholly owned subsidiary (“Purchaser”), KAC Merger Sub 2, a Cayman Islands exempted company and wholly owned subsidiary of Purchaser (“Merger Sub”), NR Instant Produce Public Company Limited, company formed under the laws of Thailand, and Bamboo Mart Limited, a Cayman Islands exempted company (the “Bamboo Mart”).

On July 18, 2024, the parties agreed to amend the merger consideration to $188,000,000 with two portions of earn out payments.

Results of Operations

We have neither engaged in any operations nor generated any operating revenues to date. Our only activities for the period from March 24, 2021 (inception) through March 31, 2025 have been organizational activities and those necessary to prepare for the Initial Public Offering and, after the Initial Public Offering, identifying a target company for a business combination. We do not expect to generate any operating revenues until after the completion of our initial business combination. We will generate non-operating income in the form of interest income on cash and cash equivalents held after the Initial Public Offering. The Company is in process of liquidating the trust account and redeeming the Public Shares and the Business Combination is terminated. The Company expects to incur significant costs in connection with the liquidation of trust account. The board of directors of the Company intends to seek to amend the Charter to remove the obligation to liquidate and dissolve the Company, such that the Company may remain listed on the OTC Markets and allow it to seek alternative opportunities, including potentially a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

For the three months ended March 31, 2025, we had net loss of $60,106, which resulted from operating costs of $169,870, offset by interest income on the operating account and the cash held in a trust account (the “Trust Account”) in the amount of $109,764.

For the nine months ended March 31, 2025, we had net loss of $272,455, which resulted from operating costs of $772,900, offset by interest income on the operating account and the cash held in the Trust Account in the amount of $500,445.

For the three months ended March 31, 2024, we had net income of $46,544, which resulted from interest income on the operating account and the cash held in a Trust Account in the amount of $204,839, offset by operating costs of $158,295.

For the nine months ended March 31, 2024, we had net income of $69,863, which resulted from interest income on the operating account and the cash and investments held in a Trust Account in the amount of $812,041, offset by operating costs of $742,178.

Liquidity and Capital Resources

On December 16, 2021, we consummated an Initial Public Offering of 7,800,000 Units (the “Units”) generating gross proceeds to the Company of $78,000,000. Simultaneously with the closing of the Initial Public Offering, the Company consummated the private sale (the “Private Placement”) of an aggregate of 357,143 Units (the “Private Placement Units”) to Kairous Asia Limited (the “Sponsor”) at a purchase price of $10.00 per Private Placement Units, generating gross proceeds to the Company in the amount of $3,571,430.

For the nine months ended March 31, 2025, net cash used in operating activities was $264,956, which was due to net loss of $272,455 and interest income on investments held in the Trust Account of $500,445, partially offset by changes in operating assets and liabilities of $507,944.

For the nine months ended March 31, 2024, net cash used in operating activities was $500,040, which was due to net income of $69,863 and interest income on investments held in the Trust Account of $812,040, partially offset by changes in operating assets and liabilities of $242,137.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements as of March 31, 2025.

Contractual Obligations

Registration Rights

The holders of the founder shares, Private Placement Units, shares being issued to the underwriters of the Initial Public Offering, and ordinary shares that may be issued on conversion of Extension Loan and working capital loans (and in each case holders of their component securities, as applicable) will be entitled to registration rights pursuant to a registration rights agreement to be signed prior to or on the effective date of Initial Public Offering requiring the Company to register such securities for resale. The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. However, the registration rights agreement provides that the Company will not be required to effect or permit any registration or cause any registration statement to become effective until the securities covered thereby are released from their lock-up restrictions. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

Underwriting Agreement

The Company granted the underwriter a 45-day option to purchase up to 1,125,000 additional Units to cover over-allotments, if any, at the Initial Public Offering price, less the underwriting discounts and commissions, which the underwriter partially exercised in full, and the additional Units were issued on December 16, 2021.

The underwriter was paid a cash underwriting discount of $0.20 per Unit, or $1,559,900 in the aggregate. In addition, the underwriter is entitled to a deferred fee of $0.35 per Unit, or $2,730,000 in the aggregate. The deferred fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event that the Company completes a business combination, subject to the terms of the underwriting agreement.

The Company is in the process of liquidating the Trust Account and redeeming the Public Shares. The deferred underwriting fee will be not reversed until the Trust Account is liquidated.

Critical Accounting Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. As of March 31, 2025 and June 30, 2024, we did not have any critical accounting estimates to be disclosed.

Recent Accounting Standards

Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on our financial statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

As of March 31, 2025, we were not subject to any market or interest rate risk.

ITEM 4. CONTROLS AND PROCEDURES.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under Securities Exchange Act of 1934, as amended (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer, to allow timely decisions regarding required disclosure.

Evaluation of Disclosure Controls and Procedures

The Company needs to implement disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”), that are designed to ensure that information required to be disclosed in the Company’s Exchange Act reports are recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission, and that such information is accumulated and communicated to our Chief Executive Officer to allow timely decisions regarding required disclosure.

As of March 31, 2025, the Chief Executive Officer carried out an assessment, of the effectiveness of the design and operation of our then existing disclosure controls and procedures pursuant to Exchange Act Rules 13a-15(b) and 15d-15(b). As of the date of this assessment, the Chief Executive Officer concluded that the Company’s disclosure controls and procedures were not effective as of March 31, 2025 to provide reasonable assurance that such information is accumulated and communicated to our management, including our principal executive officer, as appropriate to allow timely decisions regarding required disclosures, primarily as a result of the Company’s recent failure to timely file certain forms or reports under the Securities Act of 1933 and the Securities Exchange Act of 1934.

This Form 10-Q does not include an attestation report from our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permit us to provide only management’s report in this Form 10-Q.

Changes in Internal Control Over Financial Reporting

During the most recently completed fiscal quarter, there has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

None.

Item 1A. Risk Factors.

As a smaller reporting company, we are not required to make disclosures under this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On December 16, 2021, the Company consummated its initial public offering (“IPO”) of 7,800,000 units (the “Units”) (including the issuance of 300,000 Units as a result of the underwriter’s partial exercise of the over-allotment option). Each Unit consists of one ordinary share (“Ordinary Share”), one-half of one warrant (“Warrant”) entitling its holder to purchase one Ordinary Share at a price of $11.50 per whole share, and one right to receive one-tenth (1/10) of an Ordinary Share upon the consummation of an initial business combination. The Units were sold at an offering price of $10.00 per Unit, generating gross proceeds of $78,000,000. Simultaneously with the closing of the IPO, the Company consummated a private placement (“Private Placement”) of 357,143 units (the “Private Units”) at a price of $10.00 per Private Unit, generating total proceeds of $3,571,430. A total of $78,780,000 of the net proceeds from the sale of Units in the IPO (including the over-allotment option units) and the Private Placements on December 16, 2021, were placed in a trust account established for the benefit of the Company’s public shareholders.

The Private Units are identical to the units sold in the IPO except with respect to certain registration rights and transfer restrictions. The holders of the Private Units have agreed (A) to vote the private shares underlying the Private Units (the “Private Shares”) and any public shares acquired by them in favor of any proposed business combination, (B) not to propose, or vote in favor of, an amendment to the Company’s Amended and Restated Memorandum and Articles of Association with respect to the Company’s pre-business combination activities prior to the consummation of a business combination unless the Company offers holders of IPO shares the right to receive their pro rata portion of the funds then held in the trust account, (C) not to convert any Private Shares for cash from the trust account in connection with a shareholder vote to approve our proposed initial business combination or a vote to amend the provisions of our amended and restated memorandum and articles of association relating to shareholders’ rights or pre-business combination activity and (D) that the Private Shares shall not participate in any liquidating distribution upon winding up if a business combination is not consummated. Our sponsor has also agreed not to transfer, assign or sell any of the Private Units or underlying securities (except to the same permitted transferees as the insider shares and provided the transferees agree to the same terms and restrictions as the permitted transferees of the insider shares must agree to, each as described above) until the completion of our initial business combination.

We paid a total of $1,560,000, in underwriting discounts and commissions (not including the 3.5% deferred underwriting commission payable at the consummation of initial business combination) and $552,288 for other costs and expenses related to our formation and the IPO.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not Applicable.

Item 5. Other Information.

None.

Exhibit No.		Description
31.1		Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*		Inline XBRL Instance Document
101.SCH*		Inline XBRL Taxonomy Extension Schema Document
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: July 16, 2025

	Kairous Acquisition Corp. Limited

	By:	/s/ Athiwat Apichote
		Athiwat Apichote
		Chief Executive Officer

Kairous Acquisition Corp. Ltd 10-Q